2024 ESMO Congress showcased TORL-1-23's durable responses in platinum-resistant ovarian cancer patients, prompting a Phase 2 trial, and DS-9606'

TORL BioTherapeutics presented updated Phase 1 results for its Claudin 6-targeted antibody-drug conjugate, TORL-1-23, at the 2024 ESMO Congress. The study showed durable responses in patients with Claudin 6 positive, platinum-resistant ovarian cancer, prompting plans for a Phase 2 trial. A separate trial of DS-9606, another CLDN6-targeted drug, reported early efficacy in advanced solid tumors and no significant toxicities, highlighting its potential for further investigation.

September 15, 2024
3 Articles

Further Reading